Effects of Portulaca oleracea (purslane) on liver function tests, metabolic profile, oxidative stress and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinical trial

被引:2
|
作者
Milkarizi, Narges [1 ,2 ]
Barghchi, Hanieh [1 ,2 ]
Belyani, Saba [3 ]
Bahari, Hossein [4 ]
Rajabzade, Farnood [5 ]
Ostad, Andisheh Norouzian [1 ]
Goshayeshi, Ladan [6 ,7 ]
Nematy, Mohsen [8 ]
Askari, Vahid Reza [9 ,10 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Dept Nutr, Mashhad, Iran
[2] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Iran
[3] North Khorasan Univ Med Sci, Student Res Comm, Bojnurd, Iran
[4] Mashhad Univ Med Sci, Clin Res Inst, Transplant Res Ctr, Mashhad, Iran
[5] Islamic Azad Univ, Dept Radiol, Mashhad Med Sci Branch, Mashhad, Iran
[6] Mashhad Univ Med Sci, Fac Med, Dept Gastroenterol & Hepatol, Mashhad, Iran
[7] Mashhad Univ Med Sci, Gastroenterol & Hepatol Res Ctr, Mashhad, Iran
[8] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran
[9] Mashhad Univ Med Sci, Int UNESCO Ctr Hlth Related Basic Sci & Human Nutr, Mashhad, Iran
[10] Mashhad Univ Med Sci, Pharmacol Res Ctr Med Plants, Mashhad, Iran
来源
FRONTIERS IN NUTRITION | 2024年 / 11卷
关键词
non-alcoholic fatty liver; liver steatosis; Portulaca oleracea; oxidative stress; inflammation; purslane; MONOTERPENE GLUCOSIDE; L; EXTRACT; ALKALOIDS; SUPPLEMENTATION; FLAVONOIDS; DAMAGE; STAGE; SEEDS;
D O I
10.3389/fnut.2024.1371137
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disease. Portulaca oleracea exhibits anti-oxidant, anti-inflammatory, and hepatoprotective effects. This clinical trial aimed to investigate the potential benefits of Portulaca oleracea in improving NAFLD. Methods: This double-blind, randomized clinical trial enrolled 70 patients with NAFLD assigned to either the intervention group (n = 35) or placebo group (n = 35) using stratified block randomization. The intervention group received 700 mg Portulaca oleracea supplement for eight weeks, while the control group received placebo capsules. In addition, all participants received a calorie-restricted diet. Liver steatosis and fibrosis were assessed using elastography along with liver function and metabolic tests, blood pressure measurements, body composition analysis and dietary records pre-and post-intervention. Results: The average age of the participants was 44.01 +/- 8.6 years, of which 34 (48.6%) were women. The group receiving Portulaca oleracea showed significant weight changes, body mass index, fat mass index, and waist circumference compared to the placebo (p < 0.001). In addition, blood sugar, lipid profile, liver enzymes aspartate and alanine transaminase, gamma-glutamyl transferase, and systolic blood pressure were significantly improved in the intervention group compared to those in the placebo (p < 0.05). During the study, inflammatory and oxidative stress indicators, improved significantly (p < 0.05). Based on the elastography results, the hepatorenal ultrasound index and liver stiffness decreased significantly in the Portulaca oleracea group compared to the placebo (p < 0.001). Conclusion: The present clinical trial showed that receiving Portulaca oleracea supplement for eight weeks can improve the condition of liver steatosis and fibrosis in patients with NAFLD.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease
    Ore, Ayokanmi
    Akinloye, Oluseyi Adeboye
    MEDICINA-LITHUANIA, 2019, 55 (02):
  • [22] Effects of sumac (Rhus coriaria) on lipid profile, leptin and steatosis in patients with non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled trial
    Ehsani, Simin
    Zolfaghari, Hamid
    Kazemi, Samira
    Shidfar, Farzad
    JOURNAL OF HERBAL MEDICINE, 2022, 31
  • [23] Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial
    Ebrahimi-Mameghani, Mehrangiz
    Sadeghi, Zahra
    Farhangi, Mandieh Abbasalizad
    Vaghef-Mehrabany, Elnaz
    Aliashrafi, Soodabeh
    CLINICAL NUTRITION, 2017, 36 (04) : 1001 - 1006
  • [24] Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial
    Izadi, Fatemeh
    Farrokhzad, Amirhosein
    Tamizifar, Babak
    Tarrahi, Mohammad Javad
    Entezari, Mohammad Hassan
    PHYTOTHERAPY RESEARCH, 2021, 35 (01) : 477 - 485
  • [25] Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial
    Darabi, Zahra
    Darand, Mina
    Yari, Zahra
    Hedayati, Mehdi
    Faghihi, Amirhosein
    Agah, Shahram
    Hekmatdoost, Azita
    BMC RESEARCH NOTES, 2019, 12 (1) : V
  • [26] Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial
    Zahra Darabi
    Mina Darand
    Zahra Yari
    Mehdi Hedayati
    Amirhosein Faghihi
    Shahram Agah
    Azita Hekmatdoost
    BMC Research Notes, 12
  • [27] Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial
    Panahi, Yunes
    Kianpour, Parisa
    Mohtashami, Reza
    Atkin, Stephen L.
    Butler, Alexandra E.
    Jafari, Ramezan
    Badeli, Roghayeh
    Sahebkar, Amirhossein
    PHYTOTHERAPY RESEARCH, 2018, 32 (07) : 1382 - 1387
  • [28] Daily Consumption of the Capparis spinosa Reduces Some Atherogenic Indices in Patients with Non-alcoholic Fatty Liver Disease: A Randomized, Double-blind, Clinical Trial
    Khavasi, Narjes
    Somi, Mohammadhossein
    Khadem, Ebrahim
    Ayati, Mohammad Hossein
    Torbati, Mohamadali
    Fazljou, Seyyed Muhammad Bagher
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2018, 20 (11)
  • [29] The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial
    Jazayeri-Tehrani, Seyed Ali
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Qorbani, Mostafa
    Alavian, Seyed Moayed
    Daneshi-Maskooni, Milad
    Hosseinzadeh-Attar, Mohammad-Javad
    NANOMEDICINE JOURNAL, 2018, 5 (02) : 67 - 76
  • [30] The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
    Mirhafez, Seyed Reza
    Azimi-Nezhad, Mohsen
    Dehabeh, Maryam
    Hariri, Mitra
    Naderan, Ronika Danesh
    Movahedi, Ali
    Abdalla, Mohammed
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND IMPLICATIONS FOR HUMAN HEALTH, 2021, 1308 : 25 - 35